number of access : ?
number of downloads : ?
ID 115614
Title Alternative
NAFLD with elevation of alanine aminotransferase levels at various stages of metabolic syndrome
Author
Sogabe, Masahiro Tokushima University|Shikoku Central Hospital of the Mutual aid Association of Public School Teachers Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Okahisa, Toshiya Tokushima University|Shikoku Central Hospital of the Mutual aid Association of Public School Teachers Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Kurihara, Takeshi Shikoku Central Hospital of the Mutual aid Association of Public School Teachers
Kagemoto, Kaizo Tokushima University
Okazaki, Jun Tokushima University
Nakasono, Masahiko Tsurugi Municipal Handa Hospital
Content Type
Journal Article
Description
Background
The prevalence of nonalcoholic fatty liver disease (NAFLD) in the non-obese population has increased and NAFLD is not always recognized in individuals with metabolic syndrome (MS). The risk of cirrhosis is higher in patients having NAFLD with elevated alanine aminotransferase (ALT) levels than in those having NAFLD with normal ALT levels.
Objective
To measure the differences in clinical factors associated with NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and to measure differences in metabolites between MS subjects with and without NAFLD having elevation of ALT.
Methods
Among 7,054 persons undergoing health check-ups, we included 3,025 subjects who met the selection criteria. We measured differences in clinical factors for NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and compared metabolites between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS.
Results
The prevalence of NAFLD and NAFLD having elevation of ALT was significantly progressively greater in subjects with Non-MS, Pre-MS, and MS (p <0.001, respectively). In the Non-MS group, there were significant differences between subjects with and without NAFLD having elevation of ALT with respect to body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, hemoglobin A1c, uric acid, aspartate aminotransferase (AST); In the Pre-MS group, there were significant differences in BMI, hypertension, AST, and gamma-glutamyl transpeptidase (GGT); In the MS group, there were significant differences in HDL-C, impaired glucose tolerance, AST, and GGT. There were significant differences in levels of metabolites of nicotinamide, inosine, and acetyl- L-carnitine between MS subjects with and without NAFLD having elevation of ALT (all p <0.05).
Conclusions
Although NAFLD having elevation of ALT is important for development of NAFLD, differences in factors associated with NAFLD having elevation of ALT at various stages of MS should be considered. Additionally, several metabolites may play roles in the identification of risk for NAFLD in individuals with MS.
Journal Title
PLOS ONE
ISSN
19326203
Publisher
PLOS
Volume
15
Issue
8
Start Page
e0238388
Published Date
2020-08-31
Rights
© 2020 Sogabe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences
University Hospital